Karolina Akinosoglou
Overview
Explore the profile of Karolina Akinosoglou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoumas I, Andrikou I, Simantiris S, Grigoriou K, Dima I, Terentes-Printzios D, et al.
Nutr Metab Cardiovasc Dis
. 2025 Feb;
:103867.
PMID: 39986939
Background And Aims: Familial dyslipidemias are associated with increased cardiovascular risk. Increased lipoprotein(a) [Lp(a)] is considered as the most prevalent monogenic lipid disorder. The objective of the study was to...
2.
Akinosoglou K, Papageorgiou D, Gogos C, Dimopoulos G
Expert Rev Anti Infect Ther
. 2025 Jan;
:1-10.
PMID: 39881622
Introduction: Fungal infections constitute a significant global health threat, with an estimated incidence of 6.5 million invasive fungal infections and 2.5 million associated deaths each year. New antifungal agents are...
3.
Donders G, Akinosoglou K, Massie Z, Ozcelik A
Expert Opin Pharmacother
. 2025 Jan;
26(3):249-255.
PMID: 39772973
Introduction: Vulvovaginal atrophy (VVA) predominantly affects postmenopausal women due to hormonal decline but can also occur in premenopausal women with conditions such as primary ovarian insufficiency or exposure to anti-estrogen...
4.
Livieratos A, Schiro L, Gogos C, Akinosoglou K
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772104
Background/objectives: Research on respiratory virus immunity duration post-vaccination reveals variable outcomes. This study performed a literature review to assess the efficacy and longevity of immune protection post-vaccination against SARS-CoV-2, influenza,...
5.
Akinosoglou K, Livieratos A, Asimos K, Donders F, Donders G
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771534
Currently, the rising prevalence of resistant species, particularly , as well as non-albicans isolates such as and , represent challenges in their management. In this review, we aimed to explore...
6.
Marnezi M, Tsiakalos A, Akinosoglou K
Pathogens
. 2025 Jan;
13(12.
PMID: 39770388
Background: West Nile Virus [WNV] is a mosquito-borne flavivirus. It has spread globally, causing asymptomatic to severe neurological diseases in humans, with an increased risk in older adults and those...
7.
Papageorgiou D, de Lastic A, Tsachouridou O, Metallidis S, Akinosoglou K
Pathogens
. 2025 Jan;
13(12.
PMID: 39770318
Thalassemia is an inherited hematological disorder characterized by a decrease in the synthesis of or absence of one or more globin chains. Hepatitis E virus (HEV) is a major cause...
8.
Akinosoglou K, Schinas G, Papageorgiou E, Karampitsakos T, Dimakopoulou V, Polyzou E, et al.
World J Virol
. 2024 Dec;
13(4):96573.
PMID: 39722762
Background: The risk of severe coronavirus disease 2019 (COVID-19) in pregnant women is elevated. Aim: To examine the outcomes of pregnant women with COVID-19 and report perinatal outcomes and complications,...
9.
Akinosoglou K, Leventogiannis K, Tasouli E, Kakavoulis N, Niotis G, Doulou S, et al.
Int J Antimicrob Agents
. 2024 Dec;
65(2):107406.
PMID: 39647798
Background: In the ACCESS trial, the addition of clarithromycin to standard-of-care antibiotics (SoC) enhanced early clinical response and attenuated the inflammatory burden in adults with community-acquired pneumonia (CAP) requiring hospitalisation....
10.
Kyriazopoulou E, Akinosoglou K, Florou E, Kouriannidi E, Bogosian A, Tsachouridou O, et al.
Int J Antimicrob Agents
. 2024 Dec;
65(1):107405.
PMID: 39647797
Background: Anakinra was approved by the European Medicines Agency and received Emergency Use Authorization by the United States Food and Drug Administration for patients with COVID-19 pneumonia at risk for...